Core Viewpoint - HCA Healthcare Inc. is identified as one of the most undervalued large-cap stocks, with recent price target increases from RBC Capital and TD Cowen following strong Q4 2025 results and positive 2026 guidance [1][3] Group 1: Financial Performance - RBC Capital raised its price target for HCA Healthcare to $555 from $525, maintaining an Outperform rating, citing strong Q4 2025 results and robust 2026 guidance [1] - TD Cowen increased its price target from $490 to $529 with a Buy rating after HCA's Q4 2025 EBITDA exceeded consensus expectations, attributing this to effective expense controls [3] Group 2: Strategic Initiatives - HCA Healthcare is expected to achieve $400 million in savings from strategic resiliency initiatives, which will help offset challenges such as the expiration of enhanced premium tax credits and reduced contributions from state programs [1][2] - The company is leveraging its scale and data-driven efficiencies to drive growth despite a changing regulatory and payer landscape [2] Group 3: Company Overview - HCA Healthcare operates hospitals and related healthcare entities in the US, providing general and acute care services [4]
RBC Capital Boosts HCA Healthcare (HCA) PT to $555 on Robust 2026 Guidance